Commercializing Mutation-Agnostic Gene Therapy | Samarendra Mohanty Interview

Samarendra Mohanty, Co-Founder and President of Nanoscope Therapeutics, discusses the path to commercialization for mutation-agnostic gene therapies in this interview from the CGT Summit 2025 hosted by Charles River Laboratories. He outlines key considerations for CGT developers, including scalable manufacturing, validated QC assays, and early regulatory engagement. Learn how CDMOs like Charles River support rare disease innovation and how cost reduction strategies can expand global access to gene therapy. A must-watch for biotech leaders focused on durable, accessible treatments. https://bit.ly/4qoqdsw